Mucopenetrating lipoplexes modified with PEG and hyaluronic acid for CD44-targeted local siRNA delivery to the lungs
Source abstract
Abstract
RNA interfering technology has become a successful strategy for targeted gene silencing through the use of efficient delivery systems. A nanocarrier must be especially designed when considering unusual routes due to RNA instability in biological medium. Lung delivery provides extensive area of absorption and alveolar deposition, non-invasiveness and local action. However, biological barriers such as lung mucus are a great challenge to the efficient delivery of nanocarriers for therapeutic purpose. Here, we studied the diffusion of mucopenetrating lipoplexes (LX) modified with hyaluronic acid (HA) and polyethylene glycol (PEG) for the local delivery of siRNA to the lungs. PEG is commonly used for the design of mucus-penetrating nanoparticles, while the combination with HA polymer provides additional selective targeting to lung tumor cells overexpressing CD44 receptors. Cationic liposomes modified with HA and PEG in the respective concentrations of 10 and 15% (w/v) and 5, 10 and 15% (molar ratio) were prepared by ethanol injection and mixed with siRNA molecules for LX formation. Multiple particle tracking (MPT) was performed ex vivo to evaluate the influence of the hydrophilic polymers in the particles movement in fresh human airway mucus. In vivo LX distribution in the lungs of mice was analyzed by fluorescence microscopy after intratracheal administration. LX modified with both polymers showed increasing diffusion with Brownian-like trajectories in mucus samples along with the presence of siRNA. PEG 12% /HA 15% -LX at the charge ratio ±4:1 were more widely distributed throughout mice lungs. Non-PEGylated HA 15% -LX at the charge ratio ±4:1 diffused comparably to PEGylated LX, as opposed to non-modified LX, which were trapped in the mucus. LX interaction with A549 lung cells showed that the presence of HA improved cell uptake despite PEGylation, demonstrating that appropriate particle coating with mucoinert polymers and tuning surface charge compose an efficient strategy for siRNA delivery to CD44-expressing lung cells.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced Drug Delivery Systems · Inhalation and Respiratory Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Universidade Federal de Goias, Praça Universitária, Goiania, Brazil
Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
Funding
Conselho Nacional de Desenvolvimento Científico e Tecnológico · Fundação de Apoio à Pesquisa do Estado de Goiás · Coordenação de Aperfeiçoamento de Pessoal de Nível Superior · Financiadora de Estudos e Pesquisas · Fundação de Apoio à Pesquisa da Universidade Federal de Goiás
References (60)
Show source-provided references
1. 10.1016/j.omtn.2017.06.00510.1016/j.omtn.2017.06.005 ↗
2. 10.1007/s11095-011-0604-510.1007/s11095-011-0604-5 ↗
3. 10.1056/NEJMoa171615310.1056/NEJMoa1716153 ↗
4. 10.1080/21691401.2017.130721010.1080/21691401.2017.1307210 ↗
5. 10.1007/s40005-016-0261-010.1007/s40005-016-0261-0 ↗
6. Secher T · Eur Respir J · 2018 · 52 · PA5451
7. 10.1016/j.addr.2014.05.01710.1016/j.addr.2014.05.017 ↗
8. 10.1038/nrd215310.1038/nrd2153 ↗
9. 10.1016/j.addr.2006.07.00910.1016/j.addr.2006.07.009 ↗
10. 10.1007/BF0297699010.1007/BF02976990 ↗
11. 10.1016/j.addr.2017.10.00910.1016/j.addr.2017.10.009 ↗
12. 10.1016/j.biomaterials.2015.11.05610.1016/j.biomaterials.2015.11.056 ↗
13. 10.1016/j.addr.2017.10.00110.1016/j.addr.2017.10.001 ↗
14. 10.1016/j.addr.2017.08.01010.1016/j.addr.2017.08.010 ↗
15. 10.1016/j.jconrel.2018.07.00110.1016/j.jconrel.2018.07.001 ↗
16. 10.1016/j.biomaterials.2013.01.06410.1016/j.biomaterials.2013.01.064 ↗
17. 10.2217/nnm-2016-004710.2217/nnm-2016-0047 ↗
18. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
19. 10.1126/sciadv.160155610.1126/sciadv.1601556 ↗
20. 10.1242/jcs.103.2.29310.1242/jcs.103.2.293 ↗
21. 10.1080/1071754059095255510.1080/10717540590952555 ↗
22. 10.1016/j.addr.2015.11.01110.1016/j.addr.2015.11.011 ↗
23. 10.1016/j.ejps.2017.02.02710.1016/j.ejps.2017.02.027 ↗
24. 10.1111/j.1742-4658.2011.08071.x10.1111/j.1742-4658.2011.08071.x ↗
25. 10.1016/j.ejpb.2013.06.00310.1016/j.ejpb.2013.06.003 ↗
26. 10.1021/acs.langmuir.5b0197910.1021/acs.langmuir.5b01979 ↗
27. 10.1016/0005-2736(73)90408-210.1016/0005-2736(73)90408-2 ↗
28. 10.1089/oli.2008.016810.1089/oli.2008.0168 ↗
29. 10.1021/mp800215d10.1021/mp800215d ↗
30. Rubin BK · Am Rev Respir Dis
31. 10.1016/j.biomaterials.2008.12.07610.1016/j.biomaterials.2008.12.076 ↗
32. 10.1016/j.addr.2008.11.00210.1016/j.addr.2008.11.002 ↗
33. Derrien M · Gut Microbes
34. Netsomboon K · Eur J Pharm Biopharm
35. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev 2009; 61: 75–85.10.1016/j.addr.2008.09.008 ↗
36. 10.1146/annurev.ph.52.030190.00110510.1146/annurev.ph.52.030190.001105 ↗
37. Vieira ACC, Chaves LL, Pinheiro S, et al. Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis. Int J Pharm 2018; 536: 478–485.10.1016/j.ijpharm.2017.11.071 ↗
38. Al-Nemrawi NK, Alshraiedeh NH, Zayed AL, et al. Low molecular weight chitosan-coated PLGA nanoparticles for pulmonary delivery of tobramycin for cystic fibrosis. Pharmaceuticals 2018; 11: 28.10.3390/ph11010028 ↗
39. 10.1021/acsnano.5b0387610.1021/acsnano.5b03876 ↗
40. 10.1073/pnas.060861110410.1073/pnas.0608611104 ↗
41. Mastorakos P, Silva Al D, Boyle MP, et al. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci 2015; 112: 8720–8725.10.1073/pnas.1502281112 ↗
42. De Gennes PG. Conformations of polymers attached to an interface. Macromolecules 1980; 13: 1069–1075.10.1021/ma60077a009 ↗
43. 10.1021/nl302638g10.1021/nl302638g ↗
44. Bourganis V · Eur J Pharm Biopharm
45. Laffleur F. · J Appl Polym Sci
46. Chatterjee B · J Appl Pharm Sci
47. He Z, Liu Z, Tian H, et al. Scalable production of core-shell nanoparticles by flash nanocomplexation to enhance mucosal transport for oral delivery of insulin. Nanoscale 2018; 10: 3307–3319.10.1039/C7NR08047F ↗
48. Tian H · Adv Healthc Mater
49. Dufaÿ Wojcicki A, Hillaireau H, Nascimento TL, et al. Hyaluronic acid-bearing lipoplexes: physico-chemical characterization and in vitro targeting of the CD44 receptor. J Control Release 2012; 162: 545–552.10.1016/j.jconrel.2012.07.015 ↗
50. Olmsted SS · Biophys J
51. Qiu Y, Liu Y, Wang L, et al. Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. Biomaterials 2010; 31: 7606–7619.10.1016/j.biomaterials.2010.06.051 ↗
52. Yang C, Gao S, Dagnæs-Hansen F, et al. Impact of PEG chain length on the physical properties and bioactivity of PEGylated chitosan/siRNA nanoparticles in vitro and in vivo. ACS Appl Mater Interfaces 2017; 9: 12203–12216.10.1021/acsami.6b16556 ↗
53. Hatakeyama H, Akita H, Harashima H. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull 2013; 36: 892–899.10.1248/bpb.b13-00059 ↗
54. Peer D, Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 2004; 6: 343–353.10.1593/neo.03460 ↗
55. Qhattal HSS, Liu X. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm 2011; 8: 1233–1246.10.1021/mp2000428 ↗
56. Qhattal HSS, Hye T, Alali A, et al. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano 2014; 8: 5423–5440.10.1021/nn405839n ↗
57. 10.1155/2013/86078010.1155/2013/860780 ↗
58. Cohen ZR, Ramishetti S, Peshes-Yaloz N, et al. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano 2015; 9: 1581–1591.10.1021/nn506248s ↗
59. Landesman-Milo D, Goldsmith M, Leviatan Ben-Arye S, et al. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett 2013; 334: 221–227.10.1016/j.canlet.2012.08.024 ↗
60. 10.1248/bpb.34.108410.1248/bpb.34.1084 ↗